ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-OR015

Nephrologist Follow-Up vs. Usual Care After an AKI Hospitalization (FUSION): A Randomized Pilot Trial

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Silver, Samuel A., Queen's University, Kingston, Ontario, Canada
  • Chan, Christopher T., Toronto General Hospital, Toronto, Ontario, Canada
  • Wald, Ron, St. Michael's Hospital, Toronto, Ontario, Canada
Background

Survivors of AKI are at increased risk of CKD and death but few patients see a nephrologist post-discharge. Our objectives were to determine the feasibility of randomizing survivors of AKI to structured follow-up with a nephrologist or usual care, as well as to collect data on clinical outcomes for event rate calculations.

Methods

We performed a 52-week randomized pilot trial in patients hospitalized with KDIGO stage 2-3 AKI in 4 hospitals in Toronto, Canada. We randomized patients to usual care or nephrologist-led follow-up within 90-days of discharge, which consisted of a standard assessment that emphasized blood pressure control, cardiovascular risk reduction, and medication safety. The feasibility outcome was the proportion of patients recruited. The primary clinical outcome was a major adverse kidney event, which is a composite of death, chronic dialysis, or a sustained decrease in eGFR≥25%, at 52-weeks post-discharge.

Results

We screened 269 patients and randomized 71 (26%) from July 2015 to June 2017 (37 to usual care and 34 to nephrology follow-up). The most common reasons for declining to participate were patient fatigue (33%) from recent hospitalization and reluctance to see additional specialists (30%). Baseline characteristics included age 65±10 years (mean, SD), 30% female, baseline eGFR 76±22mL/min/1.73m2, 47% admitted to the ICU, and median length of stay 14 (IQR 13) days. The median time from hospital discharge to nephrology follow-up was 48 (IQR 40) days, and 22/34 (65%) patients in the intervention group attended their nephrology appointment. The primary outcome occurred in 18/37 (49%) patients in the usual care group and 17/34 (50%) patients in the intervention group (P=0.91). There were no differences between usual care and the nephrology follow-up group in death (8% vs 18%, P=0.23), ≥25% decrease in eGFR (46% vs 38%, P=0.51), or rehospitalization for AKI (24% vs 24%, P=0.94). No patients in either group received maintenance dialysis.

Conclusion

Patient recruitment was lower than anticipated primarily because of patient fatigue and resistance to in-person visits post-discharge, which suggests a more pragmatic intervention may be needed that actively engages patients in its development. The high number of major adverse kidney events observed suggests more work is warranted to improve patient follow-up after AKI.